19.2(top 1%)
impact factor
1.8K(top 10%)
papers
99.9K(top 5%)
citations
147(top 2%)
h-index
19.7(top 1%)
extended IF
1.9K
all documents
112.7K
doc citations
215(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Ferroptosis, a new form of cell death: opportunities and challenges in cancerJournal of Hematology and Oncology2019924
2Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applicationsJournal of Hematology and Oncology2019866
3The biology and role of CD44 in cancer progression: therapeutic implicationsJournal of Hematology and Oncology2018802
4Ferroptosis, necroptosis, and pyroptosis in anticancer immunityJournal of Hematology and Oncology2020698
5The effects of β-glucan on human immune and cancer cellsJournal of Hematology and Oncology2009649
6Targeting the Wnt/β-catenin signaling pathway in cancerJournal of Hematology and Oncology2020625
7Exosomes in cancer: small particle, big playerJournal of Hematology and Oncology2015611
8Tumor-associated macrophages: from basic research to clinical applicationJournal of Hematology and Oncology2017607
9Next generation of immune checkpoint therapy in cancer: new developments and challengesJournal of Hematology and Oncology2018597
10Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancersJournal of Hematology and Oncology2013594
11Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapyJournal of Hematology and Oncology2019555
12Targeting mTOR for cancer therapyJournal of Hematology and Oncology2019542
13Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinomaJournal of Hematology and Oncology2015537
14SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19Journal of Hematology and Oncology2020505
15Immune checkpoint inhibitors of PD-L1 as cancer therapeuticsJournal of Hematology and Oncology2019485
16Nanomaterials for cancer therapy: current progress and perspectivesJournal of Hematology and Oncology2021456
17Wnt/beta-catenin pathway: modulating anticancer immune responseJournal of Hematology and Oncology2017448
18EZH2: a novel target for cancer treatmentJournal of Hematology and Oncology2020447
19Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacyJournal of Hematology and Oncology2019416
20Clinical applications of mesenchymal stem cellsJournal of Hematology and Oncology2012400
21A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myelomaJournal of Hematology and Oncology2018388
22Long non-coding RNA: a new player in cancerJournal of Hematology and Oncology2013382
23Mechanism of action of lenalidomide in hematological malignanciesJournal of Hematology and Oncology2009373
24Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsJournal of Hematology and Oncology2010373
25Role of platelets and platelet receptors in cancer metastasisJournal of Hematology and Oncology2018370
26The interplay between m6A RNA methylation and noncoding RNA in cancerJournal of Hematology and Oncology2019367
27Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancerJournal of Hematology and Oncology2020359
28Functions of lncRNA HOTAIR in lung cancerJournal of Hematology and Oncology2014351
29An evolving new paradigm: endothelial cells – conditional innate immune cellsJournal of Hematology and Oncology2013350
30Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical developmentJournal of Hematology and Oncology2018333
31Nanotechnology in cancer diagnosis: progress, challenges and opportunitiesJournal of Hematology and Oncology2019314
32NK cell-based cancer immunotherapy: from basic biology to clinical developmentJournal of Hematology and Oncology2021312
33Diverse functions of miR-125 family in different cell contextsJournal of Hematology and Oncology2013304
34Abscopal effect of radiotherapy combined with immune checkpoint inhibitorsJournal of Hematology and Oncology2018303
35Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumorsJournal of Hematology and Oncology2016302
36Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialJournal of Hematology and Oncology2017302
37Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucelJournal of Hematology and Oncology2018302
38A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancerJournal of Hematology and Oncology2013301
39Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapyJournal of Hematology and Oncology2019296
40Next generation of immune checkpoint inhibitors and beyondJournal of Hematology and Oncology2021293
41Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 proteinJournal of Hematology and Oncology2017291
42CircRNAs in cancer metabolism: a reviewJournal of Hematology and Oncology2019288
43New development in CAR-T cell therapyJournal of Hematology and Oncology2017282
44The role of stromal cancer-associated fibroblasts in pancreatic cancerJournal of Hematology and Oncology2017281
45Regulation of PD-L1 expression in the tumor microenvironmentJournal of Hematology and Oncology2021281
46Targeting the IDO1 pathway in cancer: from bench to bedsideJournal of Hematology and Oncology2018277
47M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinomaJournal of Hematology and Oncology2020277
48Emerging therapies for small cell lung cancerJournal of Hematology and Oncology2019273
49Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyJournal of Hematology and Oncology2016271
50Roles of METTL3 in cancer: mechanisms and therapeutic targetingJournal of Hematology and Oncology2020269